Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PVSRIPO + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PVSRIPO | PVS-RIPO|NSC-719277|NSC719277 | PVSRIPO is an oncolytic virus comprising a recombinant poliovirus/rhinovirus chimera, which targets CD155 (Necl5)-expressing tumor cells, and potentially induces enhanced anti-tumor immune response and tumor cell cytotoxicity (PMID: 21984883, PMID: 24939611). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 124 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04690699 | Phase Ib/II | PVSRIPO + unspecified PD-1 antibody | LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04577807 | Phase II | PVSRIPO + unspecified PD-1 antibody PVSRIPO | PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma | Active, not recruiting | USA | 0 |